EMD LEXIGEN RES CT CORP has a total of 25 patent applications. Its first patent ever was published in 2000. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are ALFA LAVAL AGRI INTERNAT AKTIE, INATHERYS and CENTRE HOSPITALIER REGIONAL UNIV DE MONTPELLIER.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 18 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 2 | |
#4 | EAPO (Eurasian Patent Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Machines | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Unspecified technologies | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Gillies Stephen D | 22 |
#2 | Lo Kin-Ming | 15 |
#3 | Lan Yan | 7 |
#4 | Gillies Stephen | 3 |
#5 | Verma Rakesh | 3 |
#6 | Qian Susan X | 2 |
#7 | Lo Kin Ming | 2 |
#8 | Sun Yaping | 2 |
#9 | Lauder Scott | 2 |
#10 | Wesolowski John S Jr | 2 |
Publication | Filing date | Title |
---|---|---|
US2006194952A1 | Enhancing the circulating half-life of antibody-based fusion proteins | |
EP1702069A2 | Interleukin-12 targeted to oncofoetal fibronectin | |
US2005069521A1 | Enhancing the circulating half-life of interleukin-2 proteins | |
US7067110B1 | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |